A Single-center, Open-label, Single-dose, Fixed-dose Regimen, Self-controlled Phase I Clinical Trial to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the pH-dependent Pharmacokinetics of TQ05105 Tablets

Primary objective:
To evaluate the effect of rabeprazole on the primary pharmacokinetics of TQ05105 tablets.
Secondary objective:
To assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in combination with rabeprazole in healthy study participants.
To evaluate the effect of rabeprazole on the secondary PK parameters of TQ05105 and the pharmacokinetics of its active metabolite TQ12550.

Start Date01 Jul 2026

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT07643272

/ Active, not recruitingPhase 1

An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants

This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants. The study consists of a screening period, a dosing period (Cycles 1, 2, 3, and 4), and a follow-up period. Screening must occur within 14 days prior to the first dose of study drug. Enrolled participants will be randomly assigned to one of 6 dosing sequences in the ratio of 1:1:1:1:1:1 to complete Cycles 1-3 dosing to evaluate the effect of different types of food on the PK of HMPL-760, and then to receive rabeprazole and HMPL-760 in Cycle 4 to assess the effect of PPI on the PK of HMPL-760 (see dosing sequence table for details).

Start Date30 Jun 2026

Sponsor / Collaborator

HUTCHMED (China) Ltd.

ChiCTR2600124682

/ Not yet recruitingNot ApplicableIIT

Efficacy of Saccharomyces boulardii Sachets Combined with High-Dose Dual Therapy for Helicobacter pylori Infection: A Multicenter Prospective Study

Start Date15 May 2026

Sponsor / Collaborator

The Affiliated Hospital of Guizhou Medical University

100 Clinical Results associated with Rabeprazole Sodium

100 Translational Medicine associated with Rabeprazole Sodium

100 Patents (Medical) associated with Rabeprazole Sodium

1,291

Literatures (Medical) associated with Rabeprazole Sodium

01 Jun 2026·BIOORGANIC CHEMISTRY

Rapid discovery of repurposed drugs targeting SARS-CoV-2 spike HR1 by DNA-encoded library screening

Article

Author: Wang, Fei ; Yang, Guang ; Yan, Lei ; Liu, Lili ; Wang, Fulian ; Xue, Qingao ; Liang, Ze ; Zhang, Yi

The membrane fusion process mediated by the SARS-CoV-2 spike protein is a key therapeutic target. Its heptad repeat 1 (HR1) domain forms a conserved trimeric groove critical for forming the fusion-competent six-helix bundle with HR2. We used DNA-encoded library screening to identify small molecules binding HR1. Hits including Rabeprazole-related compound E (Rab RCE), Omeprazole, Alvimopan, and Olmesartan were characterized. Biophysical assays confirmed binding, while computational simulations revealed distinct interaction modes, with Alvimopan showing high predicted affinity. Cell-cell fusion assays demonstrated potent inhibitory activity for Olmesartan and Rab RCE. Notably, Rabeprazole and Rab RCE showed partial antiviral activity against SARS-CoV-2 variants and HCoV-OC43, rescuing virus-induced apoptosis. Mechanistically, Rabeprazole competitively occupies the HR2-binding groove on HR1, blocking fusion. Our findings identify HR1-targeting molecules like Rabeprazole as promising leads for broad-spectrum coronaviral fusion inhibitors.

12 May 2026·Zhongguo zhen jiu = Chinese acupuncture & moxibustion

[Electroacupuncture combined with western medication for non-erosive reflux disease: a randomized controlled trial].

Article

Author: Chen, Guisheng ; Gu, Xiyan ; Shi, Dazhong ; Lu, Wen ; Chen, Zhaoming ; Zhang, Jianbin ; Zhou, Zhi ; Xia, Xiaofang ; Ma, Yitong ; Feng, Yulu

Objective:

To compare the clinical efficacy on non-erosive reflux disease (NERD) among electroacupuncture (EA) combined with rabeprazole sodium enteric-coated capsules, sham-EA combined with rabeprazole sodium enteric-coated capsules, and rabeprazole sodium enteric-coated capsules alone.

Methods:

A total of 156 patients with NERD were randomly assigned, at 1∶1∶1, into an EA group (52 cases, 2 cases dropped out), a sham-EA group (52 cases, 2 cases dropped out), and a western medication group (52 cases, 2 cases dropped out). In the western medication group, rabeprazole sodium enteric-coated capsules were administered orally, 20 mg, once daily and for 8 weeks. In the EA group, besides the medication as the western medication group, EA was operated at the positive reaction points along the governor vessel, Dazhui (GV14) and Baihui (GV20), etc., with continuous wave and at the frequency of 10 Hz and an electric intensity of 2-5 mA. EA was delivered once every 2 days, 3 sessions a week and for 8 weeks. In the sham-EA group, the stimulating point selection and EA operation were the same as the EA group, but without electric stimulation exerted. The scores of reflux disease questionnaire (RDQ), self-rating anxiety scale (SAS), and self-rating depression scale (SDS) were assessed before and after treatment, as well as in the 3-month follow-up; and the clinical efficacy was evaluated in each group.

Results:

After treatment and in the 3-month follow-up, the scores of RDQ and SDS were reduced in each group (P<0.05); the EA group showed the lower scores of RDQ and SDS when compared with those in the sham-EA group and the western medication group (P<0.05), and the scores of RDQ and SDS in the sham-EA group were lower than those of the western medication group (P<0.05). The SAS score was lower after treatment in comparison with that before treatment in each group (P<0.05), and the score in both the EA group and the sham-EA group was reduced in follow-up (P<0.05). After treatment and in follow-up, SAS scores in the EA group were lower than those in the sham-EA group and the western medication group, respectively (P<0.05), and the scores in the sham-EA group were lower when compared with those in the western medication group (P<0.05). The total effective rate in the EA group was 96.0% (48/50), higher than that in the sham-EA group (92.0%, 46/50) and the western medication group (86.0%, 43/50, P<0.05); and the total effective rate in the sham-EA group was higher than that in the western medication group (P<0.05).

Conclusion:

Electroacupuncture combined with rabeprazole sodium enteric-coated capsules effectively alleviates clinical symptoms and emotional disorders in patients with NERD, presenting sustained therapeutic effect; and its efficacy is superior to the combined regimen of sham-EA and rabeprazole sodium enteric-coated capsules or the administration with rabeprazole sodium enteric-coated capsules alone.

01 May 2026·Advances in mind-body medicine

Impact of Yoga and Naturopathy in a Patient with Chronic Idiopathic Axonal Polyneuropathy Associated with Metabolic Syndrome and Rheumatoid Arthritis: A Case Report.

Article

Author: Keerthi, P ; Vijay, A ; Suganthi, S ; Mooventhan, A ; Manavalan, N ; Sathiyavathi, G

Background:

Chronic idiopathic axonal polyneuropathy (CIAP) is a slowly progressive nerve disorder characterized by sensory or sensorimotor dysfunction, which is linked to type 2 diabetes mellitus, hypertension, and metabolic syndrome. CIAP affects 75 to 125 per 100 000 people, with prevalence increasing in individuals over 60 years old.

Case Study:

A 53-year-old female homemaker presented to our inpatient facility with complaints of chronic pain, burning sensation, and discoloration over both lower limbs, accompanied by numbness persisting for the past 10 years and a 15-year history of rheumatoid arthritis (RA). Despite adherence to the prescribed conventional treatment regimen (Metformin, Atorvastatin, Amlodipine, Rabeprazole sodium, Domperidone, Gabapentin, Nortriptyline hydrochloride, and Tramadol), as verified from her medical records, the patient's symptoms did not improve.

Intervention:

The patient was provided with an integrative care for one month at our yoga and naturopathy (YN) hospital, where she received a structured lifestyle intervention comprising daily yoga sessions, a calorie-restricted plant-based diet, and adjunct naturopathic therapies such as massage, hydrotherapy, mud therapy, heliotherapy, and acupuncture with reflexology.

Results:

Post-intervention assessments showed notable improvements in anthropometric measurements, inflammatory markers, lipid profile, the impact of RA on disease scores, complete blood counts, and quality of life.

Conclusion:

The findings highlight the potential of integrative medicine, combining IYN in addition to conventional medication, to address both physical and mental challenges in patients with CIAP associated with metabolic syndrome and RA. However, as this is a single case report, the findings cannot be generalized; hence, randomized controlled and pilot studies are recommended to validate the findings.

keywords:

case report, chronic idiopathic axonal polyneuropathy, integrative yoga and naturopathy, metabolic syndrome, rheumatoid arthritis.

News (Medical) associated with Rabeprazole Sodium

04 Jun 2026

·www.einpresswire.com

Althera Laboratories Appoints Dr. Arun Maseeh as Vice President – Medical Affairs

Accomplished physician-scientist brings 25 years of experience to drive medical strategy and new product development for cardiovascular and metabolic therapies. Dr. Maseeh’s career reflects a rare combination of scientific innovation, evidence generation, product development, and medical leadership. We are delighted to welcome him to Althera leadership team.” — Sanjeev Agarwal, Althera’s CEO DUBLIN, DUBLIN, IRELAND, June 4, 2026 / EINPresswire.com / -- Althera Laboratories today announced the appointment of Dr. Arun Maseeh, MD, as Vice President – Medical Affairs, strengthening the company’s global scientific leadership as it expands its cardiovascular and metabolic portfolio across Europe, Asia, Latin America, Africa, and other international markets. Dr Patrick Aubonnet, MD is transitioning to the role of Senior Advisor to the Board on key clinical trials and related matters and will continue to guide overall company strategy working closely with our CEO Mr. Sanjeev Agarwal and Dr Maseeh. Dr. Maseeh brings more than 25 years of pharmaceutical industry leadership experience spanning Medical Affairs, Clinical Development, Clinical Research, Scientific Communications, Regulatory Strategy, and Product Innovation. He will work closely with the executive leadership team, reporting to Mr. Agarwal, company’s executive team and Dr Aubonnet to advance Althera’s evidence-generation strategy, scientific engagement initiatives, and New Product Development programs. A physician-scientist by training, Dr. Maseeh earned his MBBS from Christian Medical College, Vellore (India), and his MD in Internal Medicine from Christian Medical College, Ludhiana (India). Over the course of his career, he has held leadership positions at Cadila Pharma, Syneos, Novartis, Biocon, Troikaa, and Torrent Pharmaceuticals, leading global and regional programs across cardiometabolic medicine, oncology, gastroenterology, infectious diseases, respiratory medicine, immunology, and neuroscience. Dr. Maseeh is widely recognized for his contributions to several landmark scientific and clinical development programs. He played a leadership role in the Polycap (Polypill) program, including The Indian Polycap Study (TIPS), published in The Lancet, and the Wellcome Trust-funded TIPS-3 international cardiovascular outcomes study, published in The New England Journal of Medicine. These landmark investigations helped establish the evidence base for fixed-dose cardiovascular prevention strategies and contributed significantly to the growing global acceptance of cardiovascular polypill therapy. His scientific contributions also include a pioneering role in the development and clinical advancement of intravenous Rabeprazole, participation in the multinational IMPI Trial in tuberculous pericarditis, and leadership of global clinical development and medical affairs programs across various therapeutic areas. In addition to his industry leadership, Dr. Maseeh serves as a scientific reviewer and advisor for multiple peer-reviewed journals and was recognized as an Outstanding Manuscript Reviewer by The Annals of Internal Medicine, the flagship journal of the American College of Physicians and the world’s most cited general internal medicine journal. His contributions reflect a longstanding commitment to scientific rigor, evidence-based medicine, and the advancement of medical scholarship. Mr. Sanjeev Agarwal, Chairman & Chief Executive Officer, added: “Dr. Maseeh’s career reflects a rare combination of scientific innovation, evidence generation, product development, and medical leadership. From globally influential cardiovascular prevention studies to pioneering therapeutic innovations and international clinical development programs, his contributions have had meaningful impact on both science and patient care. We are delighted to welcome him to the Althera leadership team.” Commenting on his appointment, Dr. Maseeh said: “I am honored to join Althera Laboratories at such an exciting stage in the company’s evolution. Althera has built a strong reputation for scientific rigor, innovation, and commitment to improving patient outcomes. I look forward to working alongside colleagues across Althera and Vibonum, our healthcare partners, investigators, and scientific collaborators worldwide to advance evidence-based therapies that address important unmet medical needs in cardiovascular and metabolic health.” About Althera Laboratories Althera Laboratories is a patient-focused pharmaceutical company focused on the development, manufacture, and commercialization of innovative therapies in cardiovascular and metabolic therapeutic areas. Through its integrated scientific, manufacturing, and regulatory capabilities, including the Vibonum manufacturing platform, Althera serves healthcare professionals and patients across multiple international markets with a commitment to quality, innovation, and evidence-based healthcare. Da Luz Mathieu Althera Laboratories +41 79 954 75 76 email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

12 Nov 2025

·www.businesswire.com

Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida. “We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “We look forward to sharing encore data from our Phase 3 MOTION study of vimseltinib and providing updates on our DCC-3009 Phase 1 program, which demonstrate how we can expand our GIST treatment capabilities by targeting known primary and secondary drug-resistant mutations spanning multiple KIT exons.” Oral and Poster presentation details are as follows: Title: Long-Term Efficacy and Safety of Vimseltinib in Patients (Pts) with Tenosynovial Giant Cell Tumor (TGCT): Results from the MOTION Phase 3 Trial Presenter: Silvia Stacchiotti, M.D., Fondazione IRCCS Istituto Nazionale Dei Tumori Session Title: Session 8: TGCT & Desmoid Tumor Session Date: Friday, November 14, 2025 Session Time: 2:30 – 3:30 PM ET Title: Impact of Expert-Led Education Programs on Health Care Provider (HCP) Knowledge of Gastrointestinal Stromal Tumor (GIST) Presenter: Mark Agulnik, M.D., USC Norris Comprehensive Cancer Center, University of Southern California Poster Reception: Thursday, November 13, 2025 Session Time: 5:30 – 6:30 PM ET Title: Efficacy with Vimseltinib in Patients (Pts) with Tenosynovial Giant Cell Tumor (TGCT) and Prior Colony-Stimulating Factor 1 (CSF1) Inhibitor Therapy: A Phase 2 Case Series Presenter: Andrew J. Wagner, M.D., Ph.D., Harvard Medical School, Dana-Farber Cancer Institute Poster Reception: Thursday, November 13, 2025 Session Time: 5:30 – 6:30 PM ET Title: Effect of a High-Fat Meal on the Pharmacokinetics (PK) of Vimseltinib, an Oral Inhibitor of the Colony-Stimulating Factor 1 Receptor (CSF1), in Healthy Participants Presenter: Chengyue Zhang, Ph.D., Deciphera Pharmaceuticals, LLC Poster Reception: Thursday, November 13, 2025 Session Time: 5:30 – 6:30 PM ET Title: Effect of Itraconazole (ITX) and Rabeprazole (RBP) on the Pharmacokinetics (PK) of Vimseltinib, an Oral Inhibitor of the Colony-Stimulating Factor 1 Receptor (CSF1), in Healthy Participants Presenter: Chengyue Zhang, Ph.D., Deciphera Pharmaceuticals, LLC Poster Reception: Thursday, November 13, 2025 Session Time: 5:30 – 6:30 PM ET Title: An Open-Label Phase 1/2 Study of DCC-3009 Monotherapy in Patients (Pts) with Advanced Gastrointestinal Stromal Tumor (GIST) Presenter: Suzanne George, M.D., Division of Sarcoma, Dana-Farber Cancer Institute - Sarcoma Center Poster Reception: Thursday, November 13, 2025 Session Time: 5:30 – 6:30 PM ET About Deciphera Pharmaceuticals Inc. Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic and autoimmune disease. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera’s platform in clinical studies, QINLOCK® (ripretinib) is Deciphera’s switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity, and in the European Union for adult patients with TGCT associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera). About Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en . Cautionary Note Regarding Forward-Looking Statements In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.

Phase 2Phase 1Phase 3Drug Approval

02 Jun 2025

·www.eisai.com

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan

For Print June 2, 2025 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the launch of “Pariet® S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn and stomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan. 1 "Pariet S" is the first proton pump inhibitor (PPI 2) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product 3, works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessive acid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief. Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical under the brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders. In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life. For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets 1 "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale 2 Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process. 3 Contains rabeprazole10mg per tablet Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 [Notes to editors] Product Outline 1. Product Name: “Pariet® S” (RX-to-OTC switch, pharmaceutical requiring guidance) 2. Ingredients: Per daily dose of one tablet: rabeprazole sodium 10mg Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate 3. Indications and Usage: Stomach pain, heartburn, and bloating (This medicine contains a proton pump inhibitor which suppresses stomach acid secretion.) 4. Dosage and Administration: Adults (15 years and older): 1 tablet once daily. Do not use this medicine consecutively for more than two weeks. 5. Packaging and Recommended Retail Price (excluding tax): Packaging: 6 tablets, Recommended retail price: 1,480 yen 6. Manufactured and marketed by: Eisai Co., Ltd. Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate Full text

Drug Approval

100 Deals associated with Rabeprazole Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D00724	Rabeprazole Sodium	A02BC04	DBSALT000552

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Helicobacter pylori infection	United States	Aytu Biopharma, Inc.	26 Mar 2013
Helicobacter Infections	South Korea	Genuone Sciences, Inc.	21 Feb 2000
Stomach Ulcer	South Korea	Genuone Sciences, Inc.	21 Feb 2000
Duodenal Ulcer	United States	Waylis Therapeutics LLC	19 Aug 1999
Gastroesophageal Reflux	United States	Waylis Therapeutics LLC	19 Aug 1999
Anastomotic ulcer	Japan	Eisai Co., Ltd.	14 Oct 1997
Esophagitis, Peptic	Japan	Eisai Co., Ltd.	14 Oct 1997
Non-erosive gastro-esophageal reflux disease	Japan	Eisai Co., Ltd.	14 Oct 1997
Zollinger-Ellison Syndrome	Japan	Eisai Co., Ltd.	14 Oct 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Upper gastrointestinal hemorrhage	Phase 3	China	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	18 Jan 2017
Laryngitis	Phase 3	United States	Pricara	01 Aug 2003
Laryngopharyngeal Reflux	Phase 3	United States	Pricara	01 Aug 2003
Non-erosive reflux disease	Phase 3	-	Janssen Pharmaceutica NV	01 Oct 2001
Asthma	Phase 3	United States	Pricara	01 Oct 2000
gastric ulcer benign	Phase 1	China	Hunan Mingrui Pharmaceutical Co. Ltd.	08 May 2018
gastric ulcer benign	Phase 1	China	Beijing Huarui Dingxin Technology Co., Ltd	08 May 2018
Gastrinoma	Phase 1	China	Hunan Mingrui Pharmaceutical Co. Ltd.	08 May 2018
Gastrinoma	Phase 1	China	Beijing Huarui Dingxin Technology Co., Ltd	08 May 2018
Hemorrhage	Phase 1	China	Hubei Jumpcan Pharmaceutical Co., Ltd.	27 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DDW 12024 \| DDW 22024	Not Applicable	First line	720	14-day vonoprazan triple therapy	sfpjvqhkro(ccnhjmrffj) = ttvhymeaql mkjrevrnzb (tltwrbpdtl, 90.1 - 96.5)	Positive	18 May 2024
				14-day vonoprazan high-dose dual therapy	sfpjvqhkro(ccnhjmrffj) = htyfbomfrv mkjrevrnzb (tltwrbpdtl, 82.0 - 90.6)
NCT05152004 (Pubmed \| Infect Dis Ther)	Not Applicable	Helicobacter pylori infection	243	HDDT group	orbbuqhccu(ycvfjiansa) = aukiswttro zgmlyammha (ojngughieg ) View more	-	03 May 2023
				HT group	orbbuqhccu(ycvfjiansa) = aboadikqzh zgmlyammha (ojngughieg ) View more
NCT03658733 (Pubmed \| Clin Transl Gastroenterol)	Phase 4	Helicobacter pylori infection	65	Esomeprazole 40 mg or rabeprazole 20 mg	pbqpugcrot(twolcaniut) = 23.4% (15/64) of patients experienced drug-related TEAEs ktryorzeye (yngxtwtczo )	-	01 Aug 2021
				Amoxicillin 1,000 mg
NCT02605395 (CTgov)	Phase 4	Gastrointestinal Diseases	70	Idiazole (Idiazole 20 mg)	vfswdgrixh(lxgovasuct) = viwvqznepd afszbyinqy (zqvsphcuiw, 158.60) View more	-	01 Oct 2018
				Pariet (Pariet 20 mg)	vfswdgrixh(lxgovasuct) = rifoauidkw afszbyinqy (zqvsphcuiw, 179.24) View more
NCT02446483 (CTgov)	Phase 4	Gastrointestinal Diseases	60	Rabeprazole (Treatment A- Rabeprazole 20 mg)	ennghznqnf(khcvmbekmz) = ujntzggybf ybkkwfbboy (puvfgxzfsb, 35.67) View more	-	14 Jun 2017
				Rabeprazole (Treatment B- Rabeprazole 20 mg)	ennghznqnf(khcvmbekmz) = tigqtrlbkw ybkkwfbboy (puvfgxzfsb, 32.98) View more
NCT00911534 (CTgov)	Phase 3	Gastroesophageal Reflux	305	placebo (Placebo)	iqdsllkilo(xhuizhvufu) = rmwrycainq lubdvkedtm (tbzlzaetwc, 26.8) View more	-	02 Feb 2016
				RAB ER (RAB ER 50mg)	iqdsllkilo(xhuizhvufu) = ealacajjbb lubdvkedtm (tbzlzaetwc, 34.49) View more
NCT00658528 (CTgov)	Phase 3	Gastroesophageal Reflux	1,061	ESO (ESO 40 mg)	dkevhhuiuh = pptpnekdsa ioeczcchua (flpqgvfsbf, klocodnypz - ypugctitpa) View more	-	23 Jun 2015
				placebo+ESO (RAB ER 50 mg)	dkevhhuiuh = lqfnxfkbgp ioeczcchua (flpqgvfsbf, vqssoweibq - ingrovgftu) View more
NCT00658632 (CTgov)	Phase 3	Gastroesophageal Reflux	1,397	ESO (ESO 40 mg)	bmjarcosog = fdyssrudzd tbfbkwfbvw (nfidwkgzof, rfizvmhtov - czfhzjxhrf) View more	-	23 Jun 2015
				placebo+ESO (RAB ER 50 mg)	bmjarcosog = aoaerdmqjo tbfbkwfbvw (nfidwkgzof, imsjjzyxls - bcwldzdiwc) View more
NCT00658775 (CTgov)	Phase 3	Gastroesophageal Reflux	1,069	ESO (ESO 40mg)	bvvcmhpynu = zvazjiiizf qpfwnemaqr (xjdwsgfqfb, quluxbwwly - dkrqzvbcej) View more	-	23 Jun 2015
				placebo (RAB ER 50mg)	bvvcmhpynu = beoelyqidk qpfwnemaqr (xjdwsgfqfb, bcomoyrypy - mynjzgidsy) View more
NCT01397448 (CTgov)	Phase 2/3	Stomach Ulcer	472	Teprenone	xrtycmnnzs = cmynrjifpo ckvgmmvvmh (zzabjszrbt, bygglaxfdu - zuvyjzosjk) View more	-	23 Oct 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis